This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
FederalRegister.gov retrieves relevant information about this document from Regulations.gov to provide users with additional context. This information is not part of the official Federal Register document.
Food and Drug Administration, HHS.
Notice; request for comments.
The Food and Drug Administration (FDA or Agency) is announcing the availability of letters containing FDA's initial determinations and feedback on safety and effectiveness data submitted to demonstrate that certain active ingredients are generally recognized as safe and effective (GRASE) and not misbranded for use in over-the-counter (OTC) sunscreen drug products (sunscreen feedback letters). We are taking this action under the Sunscreen Innovation Act (SIA).
Submit either electronic or written comments by February 23, 2015. Sponsors may submit written requests for a meeting with FDA to discuss these proposed sunscreen orders by February 6, 2015.
Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should clearly identify the specific active ingredient(s) and docket number(s) to which the comments apply.
Kristen Hardin, Division of Nonprescription Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5491, Silver Spring, MD 20993-0002, 240-402-4246.
FDA is announcing the availability of six sunscreen feedback letters on its Web site that contain the Agency's tentative determinations and feedback on safety and effectiveness data submitted to demonstrate that certain active ingredients are GRASE and not misbranded for use in OTC sunscreen drug products. We are taking this action under the SIA (Pub. L. 113-195), enacted November 26, 2014. Before the SIA was enacted, these sunscreen feedback letters were issued to persons seeking OTC monograph status for nonprescription sunscreen active ingredients using the Time and Extent Application (TEA) process under FDA regulations in 21 CFR 330.14, and were also previously made available to the public in the docket.
The SIA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to, among other things, provide an alternative process for FDA to review the safety and effectiveness of nonprescription sunscreen active ingredients. The SIA establishes new procedures for establishing the conditions under which sunscreens containing active ingredients that have been reviewed through the SIA process and found in a final sunscreen order to be GRASE and not misbranded may be marketed in the United States.
Section 586C(b)(3) of the FD&C Act, as added by the SIA, provides that sunscreen feedback letters issued before the SIA was enacted are deemed to be proposed sunscreen orders. Proposed sunscreen orders contain FDA's tentative determination that a nonprescription sunscreen active ingredient or combination of nonprescription sunscreen active ingredients: (A) Is GRASE and not misbranded if marketed in accordance with such order; (B) is not GRASE and is misbranded; or (C) is not GRASE and is misbranded because the data are insufficient to classify the active ingredient or combination of ingredients as GRASE and not misbranded, and additional data are necessary to allow FDA to determine otherwise. All of the proposed sunscreen orders addressed in this notice have been tentatively classified under category (C), as described in the previous sentence. Accordingly, additional data will be needed to support a determination that any or all of the active ingredients they address are GRASE and not misbranded.
The six feedback letters that are deemed to be proposed orders under the SIA are identified in Table 1. They can be viewed electronically on FDA's Web site at http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/ucm239463.htm, under the heading “FDA Regulatory Action on Sunscreen.” Related documents, including safety and efficacy data submissions, can be accessed in the corresponding dockets, identified in Table 1, at http://www.regulations.gov. The letters and associated information may also be viewed by visiting FDA's Division of Dockets Management (see ADDRESSES ).
| Active ingredient | Sponsor | Date issued | Docket No. 1 |
|---|---|---|---|
| Bemotrizinol | Ciba Specialty Chemicals Corp | 11/13/2014 | FDA-2005-N-0453 |
| Bisoctrizole | Ciba Specialty Chemicals Corp | 9/3/2014 | FDA-2005-N-0453 |
| Drometrizole Trisiloxane | L'Oreal USA Products, Inc. | 8/29/2014 | FDA-2003-N-0196 |
| Octyl Triazone | BASF AG | 6/23/2014 | FDA-2003-N-0196 |
| Amiloxate | Symrise, Inc. Ego Pharmaceuticals Pty. Ltd. | 2/25/2014 | FDA-2003-N-0196 |
| Diethylhexyl Butamido Triazone | 3V Inc. | 2/21/2014 | FDA-2006-O-0314 |
| 1 Each letter was previously posted in the docket shown in Table 1 on the date that it was issued. | |||
Sponsors may submit a written request for a meeting with FDA to discuss any of these proposed sunscreen orders (see DATES ). Submit meeting requests electronically to www.regulations.gov or in writing to the Division of Dockets Management (see ADDRESSES ), identified with the active ingredient name(s), the corresponding docket number(s) shown in Table 1, and the heading “Sponsor Meeting Request.” To facilitate your request, please also send a copy to Kristen Hardin (see FOR FURTHER INFORMATION CONTACT ).
Interested persons may submit either electronic comments about the proposed orders discussed in this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES ). It is only necessary to send one set of comments. Identify comments with the appropriate docket number(s) and active ingredient name(s) shown in Table 1 for the proposed order(s) that the comments address. Comments on this notice may be viewed in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the appropriate docket(s) at http://www.regulations.gov.
Dated: December 31, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-00002 Filed 1-6-15; 8:45 am]
BILLING CODE 4164-01-P
10 comments have been received at Regulations.gov.
Agencies review all submissions and may choose to redact, or withhold, certain submissions (or portions thereof). Submitted comments may not be available to be read until the agency has approved them.